Botulinum toxin for the treatment of lower limb cramp pain in patients with Amyotrophic Lateral Sclerosis [PDF]
, 2020 Background: Muscle cramps and pain associated with them can be seen in patients with amyotrophic lateral sclerosis (ALS) and are known to reduce the quality of life. Pharmacological treatment may not benefit all patients in treating these cramps.
Govindarajan, Raghav +2 more
core +2 more sources
The effects of memantine on prepulse inhibition. [PDF]
, 2009 Reduced prepulse inhibition (PPI) of startle provides evidence of deficient sensorimotor gating in several disorders, including schizophrenia. The role of NMDA neurotransmission in the regulation of PPI is unclear, due to cross-species differences in the
Bergsma, F +4 more
core +2 more sources
Neurology and Therapy, 2023 Introduction This multicentre, randomised, open-label, and prospective study aimed to evaluate the effectiveness of memantine (memantine solution) on speech function in patients with moderate to severe Alzheimer’s disease (AD) who were already on ...
Hee-Jin Kim +11 more
doaj +1 more source
Memantine Disrupts Motor Coordination through Anxiety-like Behavior in CD1 Mice
Brain Sciences, 2022 Memantine is an FDA approved drug for the treatment of Alzheimer’s disease. It reduces neurodegeneration in the hippocampus and cerebral cortex through the inhibition of extrasynaptic NMDA receptors in patients and mouse models.
Anton N. Shuvaev +10 more
doaj +1 more source
A small molecule ApoE4-targeted therapeutic candidate that normalizes sirtuin 1 levels and improves cognition in an Alzheimer's disease mouse model. [PDF]
, 2018 We describe here the results from the testing of a small molecule first-in-class apolipoprotein E4 (ApoE4)-targeted sirtuin1 (SirT1) enhancer, A03, that increases the levels of the neuroprotective enzyme SirT1 while not affecting levels of neurotoxic ...
Bai, Dongsheng +14 more
core +3 more sources
Cochrane Database of Systematic Reviews, 2006 Memantine, a low affinity antagonist to glutamate NMDA receptors, may prevent excitatory neurotoxicity in dementia.To determine efficacy and safety of memantine for people with Alzheimer's disease (AD), vascular (VD) and mixed dementia.The Specialized Register of the Cochrane Dementia and Cognitive Improvement Group was searched on 8th February 2006 ...
Mcshane, R +2 more
openaire +3 more sources
Synaptic NMDA receptors mediate hypoxic excitotoxic death [PDF]
, 2012 Excessive NMDA receptor activation and excitotoxicity underlies pathology in many neuropsychiatric and neurological disorders, including hypoxia/ischemia.
Wroge, Christine M +3 more
core +3 more sources
Memantine Improves Attentional Processes in Fragile X-Associated Tremor/Ataxia Syndrome: Electrophysiological Evidence from a Randomized Controlled Trial. [PDF]
, 2016 Progressive cognitive deficits are common in patients with fragile X-associated tremor/ataxia syndrome (FXTAS), with no targeted treatment yet established.
Avar, Merve +9 more
core +2 more sources
Contribution of Lysosome and Sigma Receptors to Neuroprotective Effects of Memantine Against Beta-Amyloid in the SH-SY5Y Cells [PDF]
Advanced Pharmaceutical Bulletin, 2020 Purpose: Memantine is an approved drug for the treatment of Alzheimer’s disease (AD). Autophagy, lysosome dysfunction, and sigma receptors have possible roles in the pathophysiology of AD.
Mojtaba Keshavarz +3 more
doaj +1 more source
Evaluating Response to High-Dose 13.3 mg/24 h Rivastigmine Patch in Patients with Severe Alzheimer's Disease [PDF]
, 2015 AIMS: To identify factors predicting improvement/stabilization on the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC) and investigate whether early treatment responses can predict long-term outcomes, during a ...
Farlow, Martin R. +4 more
core +1 more source